share_log

EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Has Successfully Concluded IND-Enabling GLP Toxicology Study For SAB-142, A Novel Immunotherapeutic For Type 1 Diabetes; Co. To Submit IND Filing Within Approximately 12 Months

EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Has Successfully Concluded IND-Enabling GLP Toxicology Study For SAB-142, A Novel Immunotherapeutic For Type 1 Diabetes; Co. To Submit IND Filing Within Approximately 12 Months

獨家:SAB 生物療法告訴賓辛加有限公司.SAB-142 已成功完成對 1 型糖尿病的新型免疫治療藥物的注入啟用 GLP 毒理學研究。在大約 12 個月內提交 IND 申請
Benzinga Real-time News ·  2023/01/10 07:33

EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Has Successfully Concluded IND-Enabling GLP Toxicology Study For SAB-142, A Novel Immunotherapeutic For Type 1 Diabetes; Co. To Submit IND Filing Within Approximately 12 Months

獨家:SAB 生物療法告訴賓辛加有限公司.SAB-142 已成功完成對 1 型糖尿病的新型免疫治療藥物的注入啟用 GLP 毒理學研究。在大約 12 個月內提交 IND 申請

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論